Since insulin resistance is the main metabolic abnormality of
T2D, there has been considerable interest in insulin-sensitizing
agents for the treatment of this disease.7–10 One of the most attractive
targets for drug development is the insulin-responsive glucose
transporter 4 (GLUT-4) protein.11,12 There is increasing evidence to
suggest that the translocation of GLUT-4 can revive insulin resistance,
therefore may lead to the discovery of the next generation
of anti-diabetic drugs
diseases, and genetic susceptibility have caused signifi-
cant rise in diabetic patients